Receptor activator of nuclear factor kappa-B ligand (RANKL)

Receptor activator of nuclear factor kappa-B ligand (RANKL) is a transmembrane or soluble protein belonging to the tumor necrosis factor (TNF) superfamily that serves as the master regulator of osteoclastogenesis (UniProt O14788). It is primarily produced by osteoblasts, osteocytes, and activated T-cells, and it exerts its biological effects by binding to its receptor, RANK, located on the surface of osteoclast precursors and mature osteoclasts (PubMed: 10358058). This binding initiates a signaling cascade involving TRAF6 and NF-kappaB, which is essential for the differentiation, fusion, and activation of bone-resorbing cells (StatPearls: Physiology, Bone Remodeling). In healthy individuals, RANKL activity is balanced by the decoy receptor osteoprotegerin (OPG), but an imbalance in the RANKL/OPG ratio is a hallmark of bone-destructive diseases such as osteoporosis, rheumatoid arthritis, and bone metastases (NCBI Gene: 10673). Pharmacological inhibition of RANKL, primarily through the monoclonal antibody denosumab, effectively halts bone resorption and is a standard treatment for reducing fracture risk and managing skeletal-related events in cancer patients (FDA: Prolia/Xgeva Label). Beyond bone metabolism, RANKL also plays a critical role in the development of the immune system and lymph node organogenesis.

Other names

Tumor necrosis factor ligand superfamily member 11TNFSF11TNF-related activation-induced cytokineTRANCEOsteoprotegerin ligandOPGLOsteoclast differentiation factorODFCD254

Inhibition of the interaction between RANKL and its receptor RANK, which prevents the recruitment of adapter proteins like TRAF6 and subsequent activation of NF-kappaB and NFATc1, thereby halting the differentiation, activation, and survival of osteoclasts.